Low energy sources are routinely used in prostate brachytherapy. (125)I is one of the most commonly used sources. Low energy (131)Cs source was introduced recently as a brachytherapy source. The aim of this study is to compare dose distributions of (125)I, (103)Pd, and (131)Cs sources in interstitial brachytherapy of prostate.
PURPOSE - An open source optimizer that generates seed distributions for low-dose-rate prostate brachytherapy was designed, tested, and validated.
BERKELEY, CA (UroToday.com) - Transperineal permanent brachytherapy is a commonly utilized and well-accepted treatment option for localized prostate cancer.
BERKELEY, CA (UroToday.com) - Permanent prostate brachytherapy (PPB) with 125I or 103Pd is a well established treatment for localized prostate cancer. Urinary morbidity, including possible acute urinary retention in 6-34%, is an important problem.
Post-implant CT-scanning is an essential part of permanent prostate brachytherapy. However, the evaluation of post-implant CT dosimetry is not straightforward due to the edema that can modify the dose to the prostate and to the organs at risk.
"Quadrella" index has been recently developed to assess oncological and functional outcomes after prostate brachytherapy (PB). We aimed to evaluate this index at 1, 2, and 3 years, using validated questionnaires, assessed prospectively.
We analyzed the rate of preserved potency after prostate brachytherapy (PB) with radioactive seeds and the impact of patient comorbidities on post-PB erectile dysfunction (ED).
We included 627 patients who were assessed for pre- and postimplant potency between 2005 and 2017.
Compression of the prostate during transrectal ultrasound-guided permanent prostate brachytherapy is not accounted for during treatment planning. Dosimetry effects are expected to be small but have not been reported.
Introduction To evaluate the implementation and dosimetric outcomes of magnetic resonance imaging (MRI) planning for improved target and normal tissue definition for the treatment of prostate cancer with high-dose-rate brachytherapy (HDRBT).
Ultrasound (US)-guided high-dose-rate (HDR) prostate brachytherapy requests the clinicians to place HDR needles (catheters) into the prostate gland under transrectal US (TRUS) guidance in the operating room.
To investigate the feasibility of using parallel imaging compressed sensing (PICS) to reduce scan time and improve signal-to-noise ratio (SNR) in MRI-based postimplant dosimetry of prostate brachytherapy.
Single fraction treatments of 15Gy or 19Gy are common in HDR prostate brachytherapy. In vivo dosimetry (IVD) is therefore important to ensure patient safety. This study assesses clinical IVD and investigates error detection thresholds for real-time treatment monitoring.
AIM - To investigate the time course of testosterone (T) recovery after cessation of androgen deprivation therapy (ADT) in patients treated with brachytherapy.
METHODS - One-hundred and seventy-four patients treated between June 1999 and February 2009 were studied.
Objective: To investigate the time course of total testosterone (TT) recovery after cessation of androgen deprivation therapy (ADT) in Japanese patients treated with brachytherapy.Methods: In total, 125 patients with prostate cancer received 6 months of neoadjuvant ADT (nADT) followed by low-dose rate (LDR) brachytherapy.
This report highlights several important features of salvage low dose rate (LDR) brachytherapy after local recurrence following definitive external beam radiotherapy (EBRT). Most importantly, patient selection is essential for optimal outcomes.
Prostate brachytherapy is a treatment for prostate cancer using radioactive seeds that are permanently implanted in the prostate.
This study was undertaken to determine if significant seed migration occurred when our institution changed seed products by comparing patterns of seed migration in implants containing different stranding material.
Login to update email address, newsletter preferences and use bookmarks.